High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.

MLA

Jonasova, Anna, et al. “High Level of Full-Length Cereblon MRNA in Lower Risk Myelodysplastic Syndrome with Isolated 5q Deletion Is Implicated in the Efficacy of Lenalidomide.” European Journal of Haematology, vol. 95, no. 1, July 2015, pp. 27–34. EBSCOhost, https://doi.org/10.1111/ejh.12457.

APA

Jonasova, A., Bokorova, R., Polak, J., Vostry, M., Kostecka, A., Hajkova, H., Neuwirtova, R., Siskova, M., Sponerova, D., Cermak, J., Mikulenkova, D., Cervinek, L., Brezinova, J., Michalova, K., & Fuchs, O. (2015). High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide. European Journal of Haematology, 95(1), 27–34. https://doi.org/10.1111/ejh.12457

Chicago

Jonasova, Anna, Radka Bokorova, Jaroslav Polak, Martin Vostry, Arnost Kostecka, Hana Hajkova, Radana Neuwirtova, et al. 2015. “High Level of Full-Length Cereblon MRNA in Lower Risk Myelodysplastic Syndrome with Isolated 5q Deletion Is Implicated in the Efficacy of Lenalidomide.” European Journal of Haematology 95 (1): 27–34. doi:10.1111/ejh.12457.